



3<sup>rd</sup> May 2023

## **H&T Presspart and Hovione extend their collaboration to develop new high-performance dry powder inhaler technology platform**

H&T Presspart, a global supplier of drug delivery devices and components, today announced the signing of a collaborative partnership with Hovione, the specialist integrated CDMO and leader in spray drying and particle engineering, to develop H&T Presspart's Sunriser new high-performance dry powder inhaler technology platform.

H&T Presspart's innovative Sunriser technology is flexible to address both the challenges of classic carrier-based and spray-dried engineered formulations and to serve an increasing variety of dry powder formulations, new particle engineering and powder processing methods.

This partnership is an extension of a successful collaboration that has spanned several years on developing and commercializing innovative dry powder inhalation devices and will see the two companies develop a new high performance dry powder inhaler technology to meet future market needs. As part of the joint development agreement, H&T Presspart will remain responsible for the development and manufacturing of the Sunriser device.

To provide further insights into the benefits of this partnership for the industry, a joint workshop will be held at the Respiratory Drug Delivery (RDD) Europe 2023 on May 3<sup>rd</sup>. The workshop entitled 'Integrated development for Capsule-based DPIs- Solutions for New Challenges' will be delivered by Dr. Mirjam Kobler (H&T Presspart), Susana Saldanha (Hovione) and João Pereira (Hovione).

Christian Krätzig, President of H&T Presspart, commented "Following our successful collaboration with Hovione on the PowdAir Plus DPI device development, we are once again extremely pleased to be working with Hovione in developing this next generation high performance DPI device. As the market leader in respiratory components and devices, this strategic partnership will allow H&T Presspart to expand its portfolio within the growing field of dry powder technology."

"New inhalable therapies are often requiring delivery of higher doses of cohesive and sensitive powders. Our priority is to ensure maximum efficiency in delivering these drugs to the right locations in the lung," says Dr. Jean-Luc Herbeaux, Hovione's CEO. He adds: "We are thrilled to expand our current partnership with H&T Presspart and combine our expertise in the fields of engineered particles and inhalers for the benefit of our customers and patients."



### **About H&T Presspart**

H&T Presspart is a market leading manufacturer of drug delivery devices and components with more than 50 years' experience and enjoys a worldwide reputation for competence, quality and innovation in the pharmaceutical market. With more than 30 engineers and scientists, H&T Presspart supports its customers in bringing to market new drug delivery devices. H&T Presspart has 4 European manufacturing sites in Germany, Spain, Switzerland and the UK and also has sales representation in China, India, the U.S.A. and Uruguay.

For more information, please visit [www.presspart.com](http://www.presspart.com)

### **H&T Presspart Contact**

Anselm Ebert | Business Development Director | Email: [Anselm.ebert@presspart.com](mailto:Anselm.ebert@presspart.com)

### **About Hovione**

Hovione is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. As a Contract Development and Manufacturing Organization (CDMO) it has a fully integrated offering of services for drug substances, drug product intermediates and drug products.

The company has four FDA inspected sites in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. Hovione provides pharmaceutical customers services for the development and compliant manufacture of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, Hovione offers a complete range of services, from API, formulation development and devices.

Hovione's culture is based on innovation, quality and dependability. Hovione was the first Chemical/ Pharmaceutical Company to become a Certified B Corp, is a member of Rx-360, EFCA and participates actively in industry quality improvement initiatives to lead new global industry standards.

For more information, please visit [www.hovione.com](http://www.hovione.com) or contact:

### **Hovione Contact**

Vanessa Romeu | Communications Director | [vromeu@hovione.com](mailto:vromeu@hovione.com) | Tel: +351 21 982 9000